2.50
Hdl Handle:
http://hdl.handle.net/10541/109508
Title:
A phase II study of sulofenur (LY186641) in gastric cancer.
Authors:
Kamthan, A; Scarffe, J Howard; Walling, J; Hatty, S; Peters, B; Coleman, R; Smyth, J F
Abstract:
Sulofenur is a novel diarylsulfonylurea with proven anti-tumor activity in murine tumor models. In this phase II study in patients with advanced gastric or gastroesophageal adenocarcinoma, 17 patients were treated with sulofenur orally at 700 mg/m2 for 14 days every 3 weeks. No tumor responses were seen. The main toxicities were anemia, methemoglobinemia and abnormalities in liver function tests. These toxicities precluded dose escalation. However, plasma levels of sulofenur, and its hydroxy and keto metabolites were probably insufficient to exert anti-tumor effect in comparison with data from murine studies. Further structure-activity studies are warranted.
Affiliation:
Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
A phase II study of sulofenur (LY186641) in gastric cancer. 1992, 3 (4):331-5 Anticancer Drugs
Journal:
Anticancer Drugs
Issue Date:
Aug-1992
URI:
http://hdl.handle.net/10541/109508
PubMed ID:
1421428
Type:
Article
Language:
en
ISSN:
0959-4973
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorKamthan, Aen
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorWalling, Jen
dc.contributor.authorHatty, Sen
dc.contributor.authorPeters, Ben
dc.contributor.authorColeman, Ren
dc.contributor.authorSmyth, J Fen
dc.date.accessioned2010-08-11T17:19:28Z-
dc.date.available2010-08-11T17:19:28Z-
dc.date.issued1992-08-
dc.identifier.citationA phase II study of sulofenur (LY186641) in gastric cancer. 1992, 3 (4):331-5 Anticancer Drugsen
dc.identifier.issn0959-4973-
dc.identifier.pmid1421428-
dc.identifier.urihttp://hdl.handle.net/10541/109508-
dc.description.abstractSulofenur is a novel diarylsulfonylurea with proven anti-tumor activity in murine tumor models. In this phase II study in patients with advanced gastric or gastroesophageal adenocarcinoma, 17 patients were treated with sulofenur orally at 700 mg/m2 for 14 days every 3 weeks. No tumor responses were seen. The main toxicities were anemia, methemoglobinemia and abnormalities in liver function tests. These toxicities precluded dose escalation. However, plasma levels of sulofenur, and its hydroxy and keto metabolites were probably insufficient to exert anti-tumor effect in comparison with data from murine studies. Further structure-activity studies are warranted.en
dc.language.isoenen
dc.subjectAnticancerous Agentsen
dc.subjectOesophageal Canceren
dc.subjectStomach Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshEsophageal Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshStomach Neoplasms-
dc.subject.meshSulfonylurea Compounds-
dc.titleA phase II study of sulofenur (LY186641) in gastric cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalAnticancer Drugsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.